Michael A. Rogawski

Michael A. Rogawski

Auto-generated profile, based on publicly available information

Michael A. Rogawski

Department of Neurology and Pharmacology, School of Medicine University of California Davis, Sacramento California USA

Research Focus & Metrics

Academic Career Length

53Years (1974-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2000 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JMJean-Pierre Mothet
Jean-Pierre Mothet
APAngèle T. Parent
Angèle T. Parent
HWHerman Wolosker
Herman Wolosker
RBRoscoe O. Brady
Roscoe O. Brady
DLDavid J. Linden
David J. Linden
SSSolomon H. Snyder
Solomon H. Snyder
Functional activity of N -methyl- d -aspartate (NMDA) receptors requires both glutamate binding and the binding of an endogenous coagonist that has been presumed to be glycine, although d -serine is a more potent agonist. Localizations of d -serine and it biosynthetic enzyme serine racemase approximate the distribution of NMDA receptors more closely than glycine. We now show that selective degradation of d -serine with d -amino acid oxidase greatly attenuates NMDA receptor-mediated neurotransmission as assessed by using whole-cell patch–clamp recordings or indirectly by using biochemical assays of the sequelae of NMDA receptor-mediated calcium flux. The inhibitory effects of the enzyme are fully reversed by exogenously applied d -serine, which by itself did not potentiate NMDA receptor-mediated synaptic responses. Thus, d -serine is an endogenous modulator of the glycine site of NMDA receptors and fully occupies this site at some functional synapses.

1 July 2004 in Nature Reviews Neuroscience
Verified
Journal Article
Open access
MRMichael A. Rogawski
Michael A. Rogawski
WLWolfgang Löscher
Wolfgang Löscher

1 March 2013 in Trends in Neurosciences
Verified
Journal Article
Closed access
ODOrrin Devinsky
Orrin Devinsky
AVAnnamaria Vezzani
Annamaria Vezzani
SNSouhel Najjar
Souhel Najjar
NLNihal C. De Lanerolle
Nihal C. De Lanerolle
MRMichael A. Rogawski
Michael A. Rogawski

1 May 2020 in Neuropharmacology
Verified
Journal Article
Closed access
GSGraeme Sills
Graeme Sills
MRMichael A. Rogawski
Michael A. Rogawski

7 August 2012 in Neurology
Verified
Journal Article
Closed access
PDF file
JFJacqueline A. French
Jacqueline A. French
GKGregory L. Krauss
Gregory L. Krauss
VBVictor Biton
Victor Biton
DSDavid Squillacote
David Squillacote
HYHaichen Yang
Haichen Yang
MRMichael A. Rogawski
Michael A. Rogawski
Objective: To assess efficacy and safety of once-daily 8 or 12 mg perampanel, a noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptor antagonist, when added to concomitant antiepileptic drugs (AEDs) in the treatment of drug-resistant partial-onset seizures. Methods: This was a multicenter, double-blind, placebo-controlled trial (ClinicalTrials.gov identifier: NCT00699972). Patients (≥12 years, with ongoing seizures despite 1–3 AEDs) were randomized (1:1:1) to once-daily perampanel 8 mg, 12 mg, or placebo. Following baseline (6 weeks), patients entered a 19-week double-blind phase: 6-week titration (2 mg/week increments to target dose) followed by a 13-week maintenance period. Percent change in seizure frequency was the primary endpoint; 50% responder rate was the primary endpoint for EU registration. Results: Of 388 patients randomized and treated, 387 provided seizure frequency data. Using this intent-to-treat population over the double-blind phase, the median percent change in seizure frequency was −21.0%, −26.3%, and −34.5% for placebo and perampanel 8 and 12 mg, respectively (p = 0.0261 and p = 0.0158 for 8 and 12 mg vs placebo, respectively). Fifty percent responder rates during the maintenance period were 26.4%, 37.6%, and 36.1%, respectively, for placebo, perampanel 8 mg, and perampanel 12 mg; these differences were not statistically significant for 8 mg (p = 0.0760) or 12 mg (p = 0.0914). Sixty-eight (17.5%) patients discontinued, including 40 (10.3%) for adverse events. Most frequent treatment-emergent adverse events were dizziness, somnolence, irritability, headache, fall, and ataxia. Conclusions: This trial demonstrated that once-daily, adjunctive perampanel at doses of 8 or 12 mg improved seizure control in patients with uncontrolled partial-onset seizures. Doses of perampanel 8 and 12 mg were safe, and tolerability was acceptable. Classification of evidence: This study provides Class I evidence that once-daily 8 and 12 mg doses of adjunctive perampanel are effective in patients with uncontrolled partial-onset seizures.

1 January 2007 in Neurotherapeutics
Verified
Journal Article
Closed access
BMBrian S. Meldrum
Brian S. Meldrum
MRMichael A. Rogawski
Michael A. Rogawski